Cerus (CERS) Projected to Post Quarterly Earnings on Monday

Cerus (NASDAQ:CERS) is expected to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of ($0.0125) per share and revenue of $63.25 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, July 30th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 3.06% and a negative return on equity of 10.19%. The business had revenue of $63.30 million during the quarter, compared to the consensus estimate of $62.90 million.

Cerus Price Performance

CERS stock opened at $2.33 on Monday. The firm has a 50 day moving average price of $2.51 and a 200-day moving average price of $2.57. Cerus has a 52-week low of $1.38 and a 52-week high of $3.47. The firm has a market capitalization of $469.54 million, a price-to-earnings ratio of -77.67 and a beta of 1.83. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.07 and a current ratio of 1.83.

Analysts Set New Price Targets

CERS has been the subject of a number of analyst reports. Wall Street Zen lowered Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. Freedom Broker initiated coverage on Cerus in a research note on Thursday, August 20th. They set a “buy” rating and a $6.50 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a report on Monday, September 14th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.25.

Insiders Place Their Bets

In related news, insider Chrystal Jensen sold 30,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $2.98, for a total transaction of $89,400.00. Following the transaction, the insider owned 936,657 shares in the company, valued at $2,791,237.86. This represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.30% of the stock is currently owned by company insiders.

Cerus Company Profile

Cerus Corporation is a biomedical products company focused on improving the safety of blood transfusions. Headquartered in Concord, California, the company develops and commercializes technologies designed to reduce the risk of transfusion-transmitted infections and other threats to the blood supply.

Its principal product platform is the INTERCEPT Blood System, which uses pathogen-reduction technology to treat donated blood components. The system is available for platelets and plasma in multiple markets and is designed to inactivate a broad range of viruses, bacteria, parasites and other pathogens.